What’s the current market cap for Medacta Group SA stock?

Medacta Group SA (MOVE) has a market cap of Fr.2.7bn as of June 17, 2026.

What is the P/E ratio for Medacta Group SA stock?

The price to earnings (P/E) ratio for Medacta Group SA (MOVE) stock is 30.66 as of June 17, 2026.

Does Medacta Group SA stock pay dividends?

Yes, the Medacta Group SA (MOVE) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is Fr.1.1 and the yield is 0.41%. Medacta Group SA has a payout ratio of 15.36% on a trailing twelve-month basis.

When is the next Medacta Group SA dividend payment date?

The next Medacta Group SA (MOVE) dividend payment date is unconfirmed.

What is the beta indicator for Medacta Group SA?

Medacta Group SA (MOVE) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Medacta Group SA stock | Fr.MOVE Share Price

07:00

09:05

11:10

13:15

15:20

About Medacta Group SA

Medacta Group SA is a Swiss-based company specializing in the design, production, and distribution of orthopedic medical devices. The company's core business focuses on hip and knee replacement products, as well as spine surgery and sports medicine solutions. Founded in 1999, Medacta is headquartered in Castel San Pietro, Switzerland. The company distinguishes itself through its commitment to medical education, providing training and resources to healthcare professionals to enhance surgical outcomes. Medacta also emphasizes innovation in minimally invasive surgical techniques and personalized solutions to improve patient care and recovery times.

Ticker

Fr. MOVE

Sector

Health

Primary listing

XSWX

Employees

2,036

Headquarters

Castel San Pietro, Switzerland

Website

www.medacta.com

Medacta Group SA Metrics

BasicAdvanced

CHF 2.7bn

30.66

CHF 4.40

1.00

CHF 1.10

0.41%

Bulls say / Bears say

Adjusted EBITDA in H2 FY2025 of €92M came in 3% ahead of consensus, driven by cost savings in sales and marketing, highlighting strong operational efficiency (Reuters).

Operating cash flow surged 42.5% to €152.7M and free cash flow improved to €15.7M despite heavy capital spending, underscoring robust cash generation and financial health (Reuters).

Management raised midterm constant currency revenue growth guidance to 12%-15% for 2024-27 (up from 10%-14%) and targets a 50bp increase in EBITDA margin for FY2026, reflecting confidence in sustainable long-term growth (Reuters).

Gross profit margins were negatively impacted by foreign exchange movements in FY2025, signaling vulnerability to currency fluctuations and potential margin pressure (Reuters).

Free cash flow remained limited at €15.7M, constrained by €137M in capital expenditures predominantly allocated to growth initiatives, indicating potential strain on liquidity and funding requirements (Reuters).

FY2026 guidance of 10%-14% constant currency revenue growth and modest 50bp margin expansion implies a notable deceleration from FY2025’s 18.5% growth rate, suggesting near-term headwinds in scaling key markets (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy Fr. MOVE

Fr.

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Adjusted EBITDA in H2 FY2025 of €92M came in 3% ahead of consensus, driven by cost savings in sales and marketing, highlighting strong operational efficiency (Reuters).

Operating cash flow surged 42.5% to €152.7M and free cash flow improved to €15.7M despite heavy capital spending, underscoring robust cash generation and financial health (Reuters).

Gross profit margins were negatively impacted by foreign exchange movements in FY2025, signaling vulnerability to currency fluctuations and potential margin pressure (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

About Medacta Group SA

Ticker

Primary listing

Employees

Headquarters

Medacta Group SA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Fr. MOVE

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Medacta Group SA/Fr. MOVE

About Medacta Group SA

Ticker

Primary listing

Employees

Headquarters

Medacta Group SA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Fr. MOVE

Upcoming events

No upcoming events

What’s the current market cap for Medacta Group SA stock?

What is the P/E ratio for Medacta Group SA stock?

Does Medacta Group SA stock pay dividends?

When is the next Medacta Group SA dividend payment date?

What is the beta indicator for Medacta Group SA?

Bulls say / Bears say